Miboplatin

Drug Profile

Miboplatin

Alternative Names: DWA 2114R; Neoplat

Latest Information Update: 10 Jul 1998

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 10 Jul 1998 Discontinued-III for Breast cancer in Japan (IV)
  • 10 Jul 1998 Discontinued-III for Ovarian cancer in Japan (IV)
  • 10 Jul 1998 Discontinued-III for Prostate cancer in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top